UCB’s ambition for patients relies on our ability to innovate and deliver highly differentiated medicines with unique outcomes. Today, following the recent acquisition of Handl Therapeutics BV, we are marking their full integration into the UCB family. This is great news as it advances our ability to develop novel treatments using state of the art gene therapy technology.
UCB has a vision to move from symptomatic treatments to disease modification and eventually towards a cure. Adeno-associated virus (AAV) mediated gene therapy offers to deliver that potential and drive a fundamental change in how diseases are treated with the ability to remove or add disease-related proteins with a single treatment. A vast array of severe diseases are amenable to gene therapy and UCB is embracing this modality to expand its capabilities and ultimately transform the lives of patients with severe diseases.
Handl Therapeutics BV is a Leuven-based, Belgium born, transformative gene therapy company with a vision to deploy the power of disease modifying in vivo gene therapy to treat complex neurodegenerative diseases. Operating in a highly collaborative manner, the company built a strong international network to access global capabilities and expertise. To this end, it combines state of the art technology platforms and scientific advances licenced from KU Leuven (Belgium), Centre for Applied Medical Research (CIMA Universidad de Navarra, Spain), University of Chile (Chile) and King’s College London (UK) to address unmet medical needs.
Over the past 90 years, we have been on an incredible journey to become the company you see today. We’ve evolved and adapted but always looked to innovate and deliver highly differentiated medicines.
by Luc Uylenbroeck, UCB
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).